Achieving Superior Treatment Durability and Outcomes In Neovascular AMD and DME
Expert retina specialists discuss the latest therapies that could reduce the treatment burden and provide superior clinical outcomes in retinal diseases.
0:00 Introduction
0:56 Need for durable treatments in nAMD and DME
4:29 Mechanism of faricimab
7:14 Highlights from clinical trials for faricimab
10:33 Post hoc analyses of faricimab clinical trials
16:24 Factors affecting retreatment decision
19:28 Durability data for faricimab
23:22 Experience with faricimab
29:06 Choosing between faricimab and high-dose aflibercept
32:51 Final remarks
Related Videos
Related Content
